| Literature DB >> 10798601 |
R K Burt1, M Brenner, W Burns, E Courier, G Firestein, B Hahn, H Heslop, C Link, H McFarland, M Roland, M Territo, G Tsokos, A Traynor.
Abstract
In phase I (safety) trials, we have demonstrated the feasibility of autologous hematopoietic stem cell transplantation (HSCT) for patients with autoimmune diseases. Although this review comments on results of our phase I trials, the focus is on phase II (efficacy) trials using gene-marked autologous stem cells.Entities:
Mesh:
Year: 2000 PMID: 10798601 DOI: 10.1023/a:1006673408343
Source DB: PubMed Journal: J Clin Immunol ISSN: 0271-9142 Impact factor: 8.317